重组人p53腺病毒联合放疗治疗鼻咽癌的临床分析-clinical analysis of recombinant human p53 adenovirus combined with radiotherapy for nasopharyngeal carcinoma.docx
- 1、本文档共43页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
重组人p53腺病毒联合放疗治疗鼻咽癌的临床分析-clinical analysis of recombinant human p53 adenovirus combined with radiotherapy for nasopharyngeal carcinoma
安徽医科大学硕士学位论文
安徽医科大学硕士学位论文
PAGE
PAGE 5
neck conventional radiotherapy continued 5 days a week and 2Gy a day and totally 6 weeks. Three days before the treatment, a week after the treatment and also a month after the treatment, the two groups were given blood routine, urine routine, hepatic function, renal function and electrocardiogram to check separately. Three days before the treatment and also a month after the treatment, both the groups were given the nasopharynx CT inspection separately. The pharynx nasalis dosage of two groups was 70 Gy/35 times, dosage of lymph nodes in cervical part was 60 Gy/30 times.
Results: 1. Two groups were both given the nasopharynx CT inspection, a month after the treatmnet, the tumor body of the control group diden’t shrink obviously, compared to before treatment.
As for the treatment group, a month after the treatment, the tumor body of the control group shrank obviously, compared to before treatment.
By self-comparison, the tumor body shrank obviously before and after the treatment and the difference had statistics meaning (P0.05).
As for the treatment group, the relative index of blood routine, routine urine test, hepatic function and renal function before and after treatment had no statistics meaning and there was no obvious abnormity.
There was no other side effects except the self-limited fever.
6 difference of emotion condition had statistics meaning between treatment group and control group(P0.05). the others had no statistics meaning in basical conditon(P> 0.05).
Conclusion: 1. The unite radiotherapy of rAd-p53 to treat nasopharyngeal carcinoma is quite effective.
2.It is safe to treat nasopharyngeal carcinoma by unite radiotherapy of rAd-p53 and the patients who have side effects can tolerate.
Keywords: P53 gene; Nasopharyngeal carcinoma; Radiotherapy
1
1
中英文缩略词表
英文缩写 英文全称 中文名称
Kb kilo base pair 千碱基对
mRNA messenger ribonucleic acid 信使核糖核酸
TACE transcatheter hepatic arterial chemoembolization
经皮肝动脉栓塞化疗术
VP virus particle
您可能关注的文档
- 综合性大学声乐表演专业发展现状分析分析——以重庆大学为例-analysis on the current situation of vocal performance major development in comprehensive universities —— taking chongqing university as an example.docx
- 城市污水深度处理mibr试验分析-analysis of mibr test for advanced treatment of municipal sewage.docx
- 伊多梅纽中埃莱特拉咏叹调哦疯狂哦暴怒的分析与演绎-the analysis and deduction of idumeniu's letra aria oh crazy oh furious.docx
- 伊多梅纽中埃莱特拉咏叹调哦 疯狂!哦 暴怒!的分析与演绎-idumeniu's letra aria oh crazy! oh, rage! analysis and deduction of.docx
- 城市居民深度休闲与主观幸福感的相关研究——以南昌市为例-research on the relationship between deep leisure and subjective well - being of urban residents —— taking nanchang city as an example.docx
- 中国私募股权投资pe基金发展分析——以xxx投资有限合伙企业为例-analysis on the development of pe funds invested by private equity in china —— taking xxx investment limited partnership as an example.docx
- 中国现代“美学”概念形成与日本渊源-the formation of chinese modern.docx
- 主位推进模式下的中英政论文构篇特点分析-an analysis of the characteristics of political papers in china and britain under the thematic progression model.docx
- 中国民营企业的制度创新——从家族制向现代企业制度的转变-institutional innovation of private enterprises in china —— transformation from family system to modern enterprise system.docx
- 成长栏目发展策略分析-analysis on development strategy of growth column.docx
- 600488_2017_#CSR_天药股份_2017年度社会责任报告_2018-03-28.pdf
- 002797_2017_#CSR_第一创业_2017年度社会责任报告_2018-04-01.pdf
- 002543_2017_#CSR_万和电气_2017年度社会责任报告_2018-04-17.pdf
- 600270_2017_#CSR_外运发展_2017年度企业社会责任报告_2018-03-26.pdf
- 002641_2017_#CSR_永高股份_2017年社会责任报告_2018-04-20.pdf
- 600644_2017_#CSR_乐山电力_2017年度社会责任报告_2018-04-12.pdf
- 002165_2017_#CSR_红宝丽_2017年度社会责任报告_2018-04-19.pdf
- 000686_2017_#CSR_东北证券_2017年度社会责任报告_2018-03-29.pdf
- 600976_2017_#CSR_健民集团_2017年社会责任报告_2018-03-27.pdf
- 000778_2017_#CSR_新兴铸管_2017年度社会责任报告_2018-04-09.pdf
文档评论(0)